Print selected from Online session09/12/2002

=> d abs bib fhitstr 1-8

L3 ANSWER 1 OF 8 USPATFULL

AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:251820 USPATFULL

TI Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, CANADA
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, San Diego, CA, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES

PA BAYER CORPORATION, Pittsburgh, PA (non-U.S. corporation)

PI US 2002137774 A1 20020926

AI US 2001-907970 A1 20010719 (9)

PRAI US 1999-115877P 19990113 (60)

DT Utility

FS APPLICATION

LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201

CLMN Number of Claims: 67

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3732

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-44-5 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 8 USPATFULL

Print selected from Online session09/12/2002

AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:78859 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Uday, Khire, Hamden, CT, UNITED STATES
Dumas, Jacques, Orange, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Joel, Renick, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA, 15205 (U.S. corporation)
PI US 2002042517 A1 20020411
AI US 2001-948915 A1 20010910 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P --19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-44-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino] carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 8 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:188813 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy P., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Handen, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001034447 A1 20011025
AI US 2001-773604 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-44-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 8 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:171152 USPATFULL
TI Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors

Print selected from Online session09/12/2002

IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jaques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., Noth Haven, CT, United States
PI US 2001027202 A1 20011004
AI US 2001-773658 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Arlington Courthouse Plaza I, Suite 1400, 2200 Clarendon Boulevard, Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-44-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 5 OF 8 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:139616 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nashnomya City, Japan

Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States

PI US 2001016659 A1 20010823
AI US 2001-773672 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3652

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-44-5 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 6 OF 8 USPATFULL

AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:123628 USPATFULL

TI omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors

IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States

Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001011136 A1 20010802
AI US 2001-773675 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, 2200 Clarendon Blvd., Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3646
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-44-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 7 OF 8 USPATFULL
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:123627 USPATFULL
TI Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 2001011135 A1 20010802

Print selected from Online session09/12/2002

AI US 2001-773659 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, Arlington Courthouse Plaza 1, Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **284461-44-5P**
(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-44-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 8 OF 8 USPATFULL
AB The present invention relates to novel quinoline derivatives and quinazoline derivatives represented by the following formula (I): ##STR1## [wherein R.sub.1 and R.sub.2 are each independently H or C.sub.1 -C.sub.4 -alkyl, or R.sub.1 and R.sub.2 together form C.sub.1 -C.sub.3 -alkylene, X is O, S or CH.sub.2, W is CH or N, and Q is a substituted aryl group or substituted heteroaryl group] and their pharmaceutically acceptable salts, having platelet-derived growth factor receptor autophosphorylation inhibitory activity, to pharmaceutical compositions containing these compounds, and to methods for the treatment of diseases associated with abnormal cell growth such as tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2000:150184 USPATFULL
TI Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
IN Kubo, Kazuo, Takasaki, Japan
Ohyama, Shinichi, Takasaki, Japan
Shimizu, Toshiyuki, Takasaki, Japan
Nishitoba, Tsuyoshi, Takasaki, Japan
Kato, Shinichiro, Takasaki, Japan
Murooka, Hideko, Takasaki, Japan

Kobayashi, Yoshiko, Takasaki, Japan
PA Kirin Beer Kabushiki Kaisha, Tokyo-to, Japan (non-U.S. corporation)
PI US 6143764 20001107
WO 9717329 19970515
AI US 1998-68660 19980506 (9)
WO 1996-JP3229 19961105
19980506 PCT 371 date
19980506 PCT 102(e) date
PRAI JP 1995-313555 19951107
JP 1996-62121 19960223
DT Utility
FS Granted
EXNAM Primary Examiner: Seaman, D. Margaret
LREP Foley & Lardner
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **190727-78-7P**
(prepn. of quinoline and quinazoline derivs. inhibiting platelet-derived growth factor receptor autophosphorylation)
RN 190727-78-7 USPATFULL
CN Urea, N-[2,5-bis(trifluoromethyl)phenyl]-N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



Print selected from Online session09/12/2002

=> s l2
L4 10 L2

=> d abs bib fhitstr 1-10

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS
GI



II



III

AB Title compds. B-NHCONH-L-(M-L1)q (I) [B = (un)substituted pyridyl, quinolinyl, isoquinolinyl; L = 5 or 6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having at least one atom; q = 1-3; with proviso that L and L1 contain 0-4 hetero atoms, e.g., N, O and S] and their pharmaceutically acceptable salts were prepd. For example, coupling of aniline II, e.g., prepd. from Et 3-hydroxybenzoate in 4-steps, with bis(trichloromethyl)carbonate followed by 3-tert-butylaniline afforded urea III. In in vitro raf kinase assays, 112-specific examples of compds. I inhibited kinase activity with IC50 values ranging from 10 nM-10 .mu.M. Compds. I are useful for the treatment of cancerous cell growth mediated by raf kinase.
AN 2002:850357 CAPLUS
DN 137:352907
TI Preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase for the treatment of tumors and/or cancerous cell growth
IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Robert, Sibley N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.
PA Bayer Corporation, USA
SO U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 758,548.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002165394	A1	20021107	US 2001-777920	20010207
	US 2002137774	A1	20020926	US 2001-907970	20010719
	WO 2002062763	A2	20020815	WO 2002-US3361	20020207
	WO 2002062763	A3	20021010		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-115877P P 19990113
US 1999-257266 B2 19990225
US 1999-425228 B2 19991022
US 2001-758548 A2 20010112
US 2001-777920 A 20010207

IT **284461-44-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)

RN 284461-44-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2002 ACS

AB Various signaling pathways can confer the malignant phenotype to a cell. Ras signaling proteins have been found to play an important role in controlling cellular growth. Raf-1 is a protein kinase that exerts its effects downstream of Ras in the mitogen-activated protein kinase pathway and is thus likely to be crucial in the development of the malignant phenotype. BAY 43-9006 is an orally administered selective inhibitor of Raf-1 and the first compd. of its class to enter clin. trials. This article describes the early clin. data of BAY 43-9006 in patients with advanced, refractory solid tumors. To date, over 60 patients have been treated as part of four Phase I clin. trials. Dose levels have ranged from 50mg once weekly to 200mg twice-daily in continuous administration. The drug has been generally well tolerated with no dose limiting toxicity yet encountered. The more common toxicities have involved the gastrointestinal tract (diarrhea, nausea, abdominal cramping) and the skin (pruritus, rash, cheilitis). Pharmacokinetic evaluations have found BAY 43-9006 to have considerable interpatient variability. However, there seems to be an increase in Cmax and AUC values with increasing dose. There is no clear effect of food on bioavailability. Splitting the dose to twice-daily administration has shown increases in Cmax and AUC values but is also accompanied by considerable interpatient variability.

AN 2002:785444 CAPLUS

TI BAY 43-9006: Early clinical data in patients with advanced solid malignancies

AU Hotte, Sebastien J.; Hirte, Hal W.
CS Department of Medicine, Hamilton Regional Cancer Centre, McMaster University and Division of Medical Oncology, Hamilton, ON, Can.
SO Current Pharmaceutical Design (2002), 8(25), 2249-2253
CODEN: CPDEFP; ISSN: 1381-6128
PB Bentham Science Publishers
DT Journal; General Review
LA English
IT **475207-59-1**
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BAY 43-9006 for patients with advanced solid neoplasm)
RN 475207-59-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2002 ACS
GI



II

AB Title compds., e.g., RNHCONHZOR1 [I; R = C6H4(CMe3)-3, 2-methoxy-5-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 2-methoxy-3-quinolyl, etc.; R1 = (un)substituted acylphenyl, -acylpyridinyl, etc.; Z = (un)substituted 1,3- or -1,4-phenylene] were prepd. Thus, 4-(H2N)C6H4OC6H4(CONHMe)-4 (prepn. given) was condensed with 3-(Me3C)C6H4NH2 and CO(OCCl3)2 to give title compd. II. Data for biol. activity of title compds. were given.

AN 2002:615574 CAPLUS

DN 137:169425

TI Preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors

IN Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Sibley, Robert N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.

PA Bayer Corporation, USA

SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062763	A2	20020815	WO 2002-US3361	20020207
	WO 2002062763	A3	20021010		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002165394	A1	20021107	US 2001-777920	20010207
PRAI	US 2001-777920	A	20010207		
	US 1999-115877P	P	19990113		
	US 1999-257266	B2	19990225		
	US 1999-425228	B2	19991022		
	US 2001-758548	A2	20010112		

OS MARPAT 137:169425

IT **284461-44-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)

RN 284461-44-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]

carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2002 ACS
GI



I



II

AB The title compds. [I; E = (un)substituted aryl, heteroaryl; A = aryl, heteroaryl, heterocyclyl; X = S, O, SO2, SO, CH2, CHOH, CO; Z = O, S; p = 0-1; q = 0-1; D = CH, T = CR8, M = C and Q = NT7p, wherein p = 0 and q = 1; or D = CH, T = CR8, M = C and Q = NR7p, wherein p =1 and q = 0, or D = CH, T = CR8, M = C and Q = S or O, wherein q = 0; or D = N, T = CR8, M = C and Q = NR7p, wherein either p or q = 0 and the other = 1; or D = CH, T = N, M = C and Q = NR7p, wherein either p or q = 0 and the other = 1; or D = CH, T = CR8, M = N and Q = CH, wherein q = 0; R1 = alkyl, haloalkyl, aryl, etc.; R2 = H, alkyl, aryl, etc.; R3 = alkylene or alkylene substituted by oxo, and is linked together with N atom to which it is attached and to one of the benzimidazole N atoms to form a heterocyclic compd. fused to the benzimidazole; R7 = H, alkyl, etc.; R8 = H, halo] and their salts, useful in the treatment of hyperproliferative diseases, were prepd. Thus, reacting Me [5-(4-aminophenoxy)-1H-benzimidazol-2-yl]carbamate (prepn. given) with 3-chlorophenyl isocyanate in THF afforded 69% II which showed pIC50 of > 7.0 in TIE-2 and VEGFR2 enzyme assays.

Print selected from Online session09/12/2002

AN 2002:428885 CAPLUS
DN 137:6179
TI Preparation of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors
IN Cheung, Mui; Harris, Philip Anthony; Hasegawa, Masaichi; Ida, Satoru; Kano, Kazuya; Nishigaki, Naohiko; Sato, Hideyuki; Veal, James Martin; Washio, Yoshiaki; West, Rob I.
PA Glaxo Group Limited, UK; Glaxosmithkline K.K.
SO PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044156	A2	20020606	WO 2001-US44553	20011128
	WO 2002044156	A3	20021017		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002032439	A5	20020611	AU 2002-32439	20011128
PRAI	US 2000-253868P	P	20001129		
	US 2001-310939P	P	20010808		
	WO 2001-US44553	W	20011128		

OS MARPAT 137:6179
IT **433224-71-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzimidazoles as TIE-2 and/or VEGFR2 inhibitors)
RN 433224-71-6 CAPLUS
CN Carbamic acid, [5-[4-[[[[2-fluoro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-1H-imidazo[4,5-b]pyridin-2-yl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS
GI



II

AB This invention relates to the prepn. and use of (hetero)aryl ureas ANHCONHB [I; A = L(ML1)q; L = 5- or 6-membered (hetero)aryl, esp. Ph or pyridinyl; M = bridging group; L1 = (hetero)aryl with at least one (un)substituted sulfamoyl, carboxy, or carbamoyl substituent; q = 1-3; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] for the treatment of raf mediated diseases, such as cancer (no data). Approx. 100 invention compds. and numerous intermediates were prepd. For instance, 3-tert-butylaniline was coupled with bis(trichloromethyl)carbonate to form the isocyanate, followed by addn. of 4-(3-N-methylcarbamoylphenoxy)aniline (prepn. given) to afford the urea II.

AN 2000:493516 CAPLUS

DN 133:120157

TI Preparation of .omega.-carboxy(hetero)aryl substituted diphenyl ureas as raf kinase inhibitors

IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PA Bayer Corporation, USA

SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000042012	A1	20000720	WO 2000-US648	20000112
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1140840	A1	20011010	EP 2000-903239	20000112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2001011135	A1	20010802	US 2001-773659	20010202
	US 2001011136	A1	20010802	US 2001-773675	20010202
	US 2001016659	A1	20010823	US 2001-773672	20010202
	US 2001027202	A1	20011004	US 2001-773658	20010202
	US 2001034447	A1	20011025	US 2001-773604	20010202
	NO 2001003463	A	20010912	NO 2001-3463	20010712

	US 2002137774	A1	20020926	US 2001-907970	20010719
	US 2002042517	A1	20020411	US 2001-948915	20010910
PRAI	US 1999-115877P	P	19990113		
	US 1999-257266	A2	19990225		
	US 1999-425228	A2	19991022		
	WO 2000-US648	W	20000112		

OS MARPAT 133:120157

IT **284461-44-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of .omega.-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-44-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS

GI



II

AB The title compds. ADB [I; D = NHCONH; A = substituted moiety of up to 40 carbon atoms of the formula L(ML1)q (wherein L = 5-6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having al least one atom; q = 1-3; each of L and L1 contains 0-4 members of the group consisting of N, O and S); B = (un)substituted up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D contg. 0-4 members of the group consisting of N, O and S], useful in treating p38 mediated diseases, were prepd. E.g., a multi-step synthesis of the urea II which showed IC50 of 1-10 .mu.M against p38, was given. Compds. I are effective at 0.01-200 mg/kg/day (oral administration).

Print selected from Online session09/12/2002

AN 2000:493376 CAPLUS
DN 133:120155
TI Preparation of .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PA Bayer Corporation, USA
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000041698	A1	20000720	WO 2000-US768	20000113
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1158985	A1	20011205	EP 2000-905597	20000113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-115878P	P	19990113		
	US 1999-257265	A2	19990225		
	US 1999-425229	A2	19991022		
	WO 2000-US768	W	20000113		

OS MARPAT 133:120155
IT **284461-86-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of .omega.-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)
RN 284461-86-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2002 ACS

AB A method of treating a p-38 mediated disease other than cancer comprises administration of BNHCONHA [A = (substituted) Ph, pyridyl, 2-thienyl; B = (substituted) aryl, heteroaryl contg. .gtoreq.1 6-membered arom. structure contg. 0-4 N, O, or S atoms]. Thus, 5-tert-butyl-2-(3-tetrahydrofuranyloxy)aniline (prepn. given) and p-tolyl isocyanate were stirred 8 h in PhMe to give 75% N-(5-tert-butyl-2-(3-tetrahydrofuranyloxy)phenyl)-N'-(4-methylphenyl)urea. Title compds. inhibited p38 kinase with IC50 = 1-10 .mu.M.

AN 1999:421667 CAPLUS

DN 131:58659

TI Preparation of diaryl ureas as inhibitors of p38 kinase.

IN Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Hatoum-Mokdad, Holia; Rodriguez, Mareli; Sibley, Robert; Wang, Ming

PA Bayer Corporation, USA

SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932463	A1	19990701	WO 1998-US27265	19981222
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2315715	AA	19990701	CA 1998-2315715	19981222
	AU 9919399	A1	19990712	AU 1999-19399	19981222
	EP 1042305	A1	20001011	EP 1998-964221	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526276	T2	20011218	JP 2000-525400	19981222
PRAI	US 1997-995749	A	19971222		
	WO 1998-US27265	W	19981222		

OS MARPAT 131:58659

IT **228399-74-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diaryl ureas as inhibitors of p38 kinase)

RN 228399-74-4 CAPLUS

CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)





RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2002 ACS
GI



II

AB The invention relates to the use of a group of aryl ureas ANHCONHB [I; A = certain (un)substituted Ph, pyridinyl, or thien-2-yl groups; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] in treating raf-mediated diseases, and pharmaceutical compns. for use in such therapy. A subset of I are novel and are claimed per se. Approx. 160 invention compds. and numerous intermediates were prepd. For instance, reaction of tolyl isocyanate with 2-methoxy-5-(trifluoromethanesulfonyl)aniline in EtOAc gave title compd. II. In an in vitro raf kinase assay, all compds. displayed IC50 values between 1 nM and 10 .mu.M.
AN 1999:421642 CAPLUS
DN 131:58658
TI Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
IN Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Rodriguez, Mareli; Wang, Ming
PA Bayer Corporation, USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932436	A1	19990701	WO 1998-US26081	19981222

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2315646	AA	19990701	CA 1998-2315646	19981222
AU 9919054	A1	19990712	AU 1999-19054	19981222
EP 1049664	A1	20001108	EP 1998-963809	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526258	T2	20011218	JP 2000-525373	19981222
BR 9814375	A	20020521	BR 1998-14375	19981222
NO 2000003230	A	20000821	NO 2000-3230	20000621
PRAI US 1997-996344	A	19971222		
WO 1998-US26081	W	19981222		

OS MARPAT 131:58658

IT **228399-74-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sym. and unsym. substituted di-Ph ureas with inhibitory effects on tumors mediated by raf kinase)

RN 228399-74-4 CAPLUS

CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2002 ACS

GI



AB The title compds. I [R1 and R2 represent each H or C1-4 alkyl, or R1 and R2 together form C1 to C3 alkylene; X represents O, S or CH2; W represents CH or N; and Q represents substituted aryl or substituted heteroaryl] are prepd. I inhibit platelet-derived growth factor receptor autophosphorylation and are useful in the treatment of cancer, arthritis, etc. The title compd. II (prepn. given) (at 100 mg/kg i.p. once daily for 9 days) increased the survival of mice with transplanted leukemic P388 cells by 130%.

AN 1997:414195 CAPLUS

DN 127:34137

TI Preparation of quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation

IN Kubo, Kazuo; Ohyama, Shinichi; Shimizu, Toshiyuki; Nishitoba, Tsuyoshi; Kato, Shinichiro; Murooka, Hideko; Kobayashi, Yoshiko; et al.

PA Kirin Beer Kabushiki Kaisha, Japan; Kubo, Kazuo; Ohyama, Shinichi; Shimizu, Toshiyuki; Nishitoba, Tsuyoshi; Kato, Shinichiro

SO PCT Int. Appl., 243 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9717329	A1	19970515	WO 1996-JP3229	19961105
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9673400	A1	19970529	AU 1996-73400	19961105
	EP 860433	A1	19980826	EP 1996-935541	19961105
	EP 860433	B1	20020703		
	R: CH, DE, FR, GB, LI				
	US 6143764	A	20001107	US 1998-68660	19980506
PRAI	JP 1995-313555	A	19951107		
	JP 1996-62121	A	19960223		
	WO 1996-JP3229	W	19961105		

OS MARPAT 127:34137

IT **190727-78-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinoline and quinazoline derivs. inhibiting platelet-derived growth factor receptor autophosphorylation)

RN 190727-78-7 CAPLUS

CN Urea, N-[2,5-bis(trifluoromethyl)phenyl]-N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2002 ACS
AB Anilines RZC6H4NH2 (R = heteroaryl, e.g., 6-chloro-3-pyridazinyl, Z = O, SO2) were prepd. and converted into their corresponding ureas, carbamates, carboxamides, and benzenesulfonamides by treatment with isocyanates, chloroformates, and acyl halides, resp.
AN 1984:510849 CAPLUS
DN 101:110849
TI Synthesis of potential plant protective agents and pesticides from substituted anilines
AU Kempter, Gerhard; Beerbalk, H. D.
CS Sekt. Chem./Biol., Paedagog. Hochsch. "Karl Liebknecht", Potsdam-Sanssouci, DDR-1500, Ger. Dem. Rep.
SO Wissenschaftliche Zeitschrift der Paedagogischen Hochschule Karl Liebknecht Potsdam (1983), 27(1), 101-20
CODEN: WPKLAO; ISSN: 0138-290X
DT Journal
LA German
OS CASREACT 101:110849
IT **91619-55-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 91619-55-5 CAPLUS
CN Urea, N-[4-(3-pyridinyloxy)phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



Print selected from Online session09/12/2002

=>

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS
GI



II

AB The title compds. ADB [I; D = NHCONH; A = substituted moiety of up to 40 carbon atoms of the formula L(ML1)q (wherein L = 5-6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having al least one atom; q = 1-3; each of L and L1 contains 0-4 members of the group consisting of N, O and S); B = (un)substituted up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D contg. 0-4 members of the group consisting of N, O and S], useful in treating p38 mediated diseases, were prepd. E.g., a multi-step synthesis of the urea II which showed IC50 of 1-10 .mu.M against p38, was given. Compds. I are effective at 0.01-200 mg/kg/day (oral administration).

AN 2000:493376 CAPLUS

DN 133:120155

TI Preparation of .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors

IN Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PA Bayer Corporation, USA

SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000041698	A1	20000720	WO 2000-US768	20000113
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1158985	A1	20011205	EP 2000-905597	20000113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-115878P	P	19990113		
	US 1999-257265	A2	19990225		
	US 1999-425229	A2	19991022		
	WO 2000-US768	W	20000113		

OS MARPAT 133:120155

IT **284461-86-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of .omega.-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)
RN 284461-86-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)